TIGIT Inhibitors Market Growth Accelerates With Expanding Immuno-Oncology Pipeline
Author : John snow | Published On : 01 Oct 2026
The TIGIT inhibitors market is positioned for substantial growth as immuno-oncology research expands across multiple cancer indications. Increasing incidence of non-small cell lung cancer (NSCLC), renal cell carcinoma, colorectal cancer, melanoma, and other solid tumors is contributing to demand for innovative treatment approaches. At the same time, growing clinical research activity around TIGIT-targeted therapies is strengthening the competitive landscape. Emerging candidates, including domvanalimab, rilvegostomig, Casdozokitug (CHS-388), and COM902, are being evaluated across several indications. DelveInsight’s analysis examines treatment patterns, epidemiology, emerging therapies, competitive dynamics, and market forecasts across the United States, EU4, the United Kingdom, and Japan through 2034.
For detailed market size and projected growth through 2034, explore the TIGIT Inhibitors Market Forecast - https://www.delveinsight.com/report-store/tigit-inhibitors-market-forecast?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
TIGIT Inhibitors Market Expands Across Major Cancer Indications
The TIGIT inhibitors market encompasses several cancer indications where immune checkpoint pathways play an important role in tumor progression and immune evasion. The principal indications assessed include renal cell carcinoma, NSCLC, colorectal cancer, head and neck squamous cell carcinoma, melanoma, esophageal squamous cell carcinoma, endometrial cancer, hepatocellular carcinoma, and other malignancies.
The United States represented the largest share of the 7MM market in 2024. The patient population analysis also highlights substantial opportunities associated with NSCLC, with approximately 205,000 incident cases reported in the United States in 2024. The expanding addressable patient population, combined with unmet treatment needs across advanced cancers, is supporting continued research into TIGIT-directed immunotherapies.
Rising Cancer Burden Supports TIGIT Inhibitors Market Development
The increasing global burden of cancer remains an important factor influencing development within the TIGIT inhibitors market. Solid tumors such as NSCLC, melanoma, and other difficult-to-treat cancers continue to create substantial clinical challenges. Although established immunotherapies have improved outcomes for numerous patients, resistance, disease progression, and limited response in certain populations continue to create areas of unmet need.
TIGIT represents an additional immune checkpoint pathway that can potentially be targeted alongside established PD-1/PD-L1 therapies. Consequently, pharmaceutical and biotechnology companies are investigating combination strategies intended to strengthen antitumor immune responses. This scientific rationale has contributed to increased research activity and investment across the TIGIT therapeutic landscape.
Discover the leading companies and competitive developments through the TIGIT Inhibitors Analysis - https://www.delveinsight.com/sample-request/tigit-inhibitors-market-forecast?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Immuno-Oncology Innovation Strengthens TIGIT Inhibitors Market Potential
The broader adoption of immune checkpoint inhibitors has created an important foundation for TIGIT-focused development. TIGIT inhibitors are being evaluated as monotherapy approaches as well as in combination with other checkpoint-targeting agents. Blocking TIGIT may help restore immune-cell activity and complement PD-1/PD-L1 inhibition.
Research has also expanded toward small-molecule TIGIT inhibitors. Experimental compounds have demonstrated potential to influence CD8+ T-cell and natural killer cell activity while interfering with TIGIT-ligand interactions. Preclinical investigations have explored mechanisms involving immune activation, macrophage-mediated phagocytosis, ferroptosis, and enhanced activity alongside PD-1/PD-L1 blockade.
Despite this progress, developers continue to face challenges related to selectivity, pharmacokinetics, pharmacodynamics, resistance, half-life, tumor penetration, and optimal combination strategies. Advances in computational modeling, structure-activity relationship studies, and rational drug design may support further development.
Leading TIGIT Inhibitors Shape Competitive Landscape
The competitive landscape includes several companies advancing potential TIGIT-targeted therapies. Key participants include Arcus Biosciences, Gilead Sciences, AstraZeneca, Compugen, Coherus Biosciences, Daiichi Sankyo, and other organizations involved in immuno-oncology research.
Domvanalimab, developed by Arcus Biosciences and Gilead Sciences, is a humanized IgG1 monoclonal antibody targeting TIGIT. Its mechanism is designed to prevent TIGIT from interacting with CD112 and CD155, potentially supporting CD226 signaling in NK cells and CD8+ T cells. Clinical development has included NSCLC and upper gastrointestinal malignancies.
Rilvegostomig, associated with AstraZeneca, Compugen, and Daiichi Sankyo, is a bispecific antibody designed to target both PD-1 and TIGIT. By simultaneously addressing these immune checkpoint pathways, the therapy is being investigated for its ability to enhance T-cell and NK-cell activity. Its clinical development includes NSCLC, head and neck squamous cell carcinoma, biliary tract cancer, and other solid tumors.
Additional candidates such as Casdozokitug (CHS-388) from Coherus Biosciences and COM902 from Compugen further contribute to pipeline diversity.
Strategic Collaborations Influence TIGIT Inhibitors Market Progress
Strategic collaborations are also supporting the development and commercialization potential of TIGIT-targeted therapies. Partnerships can provide access to development expertise, manufacturing capabilities, regulatory resources, and financial support while helping companies advance complex immuno-oncology programs.
Recent developments have highlighted continued commercial activity surrounding leading candidates. In December 2025, Compugen and AstraZeneca amended their 2018 exclusive license agreement concerning rilvegostomig, allowing Compugen to monetize part of its future royalties while supporting its broader pipeline. In October 2025, Arcus Biosciences reported overall survival results from Arm A1 of the Phase II EDGE-Gastric study evaluating domvanalimab with zimberelimab and chemotherapy in advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma.
In September 2025, Genentech presented Phase III results for tiragolumab combined with atezolizumab and bevacizumab as a first-line treatment approach in previously untreated locally advanced or metastatic hepatocellular carcinoma at ESMO 2025.
TIGIT Inhibitors Market Outlook Through 2034
Although clinical development has encountered inconsistent outcomes across some TIGIT programs, continued investigation of next-generation candidates and combination strategies remains an important feature of the market. Potential regulatory milestones for leading therapies could influence commercial opportunities and stimulate additional research across the target class.
The TIGIT inhibitors market report covers the 2020–2034 study period across the 7MM, comprising the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Its epidemiological assessment includes total cases, eligible patient populations, and treated cases across selected indications. The analysis also evaluates emerging therapies, company strategies, competitive positioning, and market opportunities.
To explore emerging TIGIT inhibitor candidates and late-stage clinical development, visit TIGIT Inhibitors Treatment - https://www.delveinsight.com/sample-request/tigit-inhibitors-market-forecast?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Conclusion
The TIGIT inhibitors market is advancing alongside broader innovation in cancer immunotherapy and checkpoint-targeted treatment. Increasing cancer incidence, persistent unmet needs, and expanding clinical research are supporting continued development of TIGIT-directed approaches. Domvanalimab, rilvegostomig, Casdozokitug, and COM902 represent important candidates within the evolving pipeline, while strategic collaborations continue to influence development activities. Research into combination therapies and small-molecule approaches is further broadening the therapeutic landscape. As clinical evidence develops and regulatory milestones emerge, the market will continue to be shaped by treatment efficacy, patient eligibility, competitive differentiation, and successful development strategies across major oncology indications through 2034.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Abhishek kumar
